ADVERTISEMENT  
May 15, 2014
CONNECT WITH SMARTBRIEF  LinkedIn Facebook Twitter YouTube 
SNMMI SmartBrief Special Report
News for nuclear medicine and molecular imaging professionals
Sign up|Forward|Archive|Advertise

SNMMI SmartBrief Special Report:
Get ready for the SNMMI Annual Meeting
St. Louis at twilight.
St. Louis at twilight. (RudyBalasko)
Meet SNMMI in St. Louis
SNMMI is preparing to welcome more than 5,000 attendees and over 150 exhibitors to the society and industry's premier event, the SNMMI Annual Meeting on June 7-11. With more than 100 continuing education sessions, networking and more, there will be plenty of chances to learn, connect and be inspired by the work of your profession. To preview the event, SNMMI SmartBrief brings you up to speed on the latest developments in the field, sure to be built upon at next month's conference in St. Louis. If you haven't registered yet, there's still time.
Emerging Tracers 
  • Will Xofigo be the first NM blockbuster?
    Emerging therapeutic radiopharmaceuticals and a solid market for diagnostic radiopharmaceuticals will help fuel average annual growth of 11% in the global nuclear medicine market, according to a MEDraysintell report. Xofigo from Bayer -- used to treat prostate and bone cancers -- is poised to be the "first blockbuster of nuclear medicine," fueling major growth in that area, and gallium-68 looks promising for use with PET diagnostic procedures. The report also projects resolution to molybdenum supply issues and notes that support from mainstream pharma is needed to continue development of nuclear medicine. DOTMed.com (5/6) LinkedInFacebookTwitterEmail this Story
  • Latest amyloid agent Vizamyl headed to first U.S. sites
    GE Healthcare has announced the first seven markets in the U.S. where Vizamyl, a diagnostic PET agent used for beta amyloid imaging, will be available. Vizamyl will be rolled out first in Dallas; Phoenix; East Rutherford, N.J.; Woburn, Mass.; Beltsville, Md.; East Lansing, Mich.; and Colton, Calif. The PET tracer is indicated for use in adult patients with cognitive impairment being assessed for cognitive decline including Alzheimer's disease. Diagnostic Imaging (4/29) LinkedInFacebookTwitterEmail this Story
  • JNM: Compound shows promise for neuroendocrine imaging
    Researchers evaluated potential compounds to determine whether they can spot neuroendocrine tumors by zeroing in on glucose-dependent insulinotropic polypeptide receptors, a type of incretin receptor. They found that the compound EG4, tested conjugated with indium-111 and gallium-68, bound to GIP receptors in mice with high affinity, showing high uptake and clear tumor visualization with PET. The study appeared in the Journal of Nuclear Medicine. MolecularImaging.net (4/30) LinkedInFacebookTwitterEmail this Story
  • Other News
  ADVERTISEMENT  
Astellas is proud to support the Society of Nuclear Medicine and Molecular Imaging.
Visit www.us.astellas.com
Imaging in Practice 
  • Molecular imaging, from the research lab to medical practice
    Silvio Aime, professor and head of the Molecular Imaging Center at the University of Turin, says many research developments in molecular imaging are poised for integration into the practice of medicine. "I think the future of molecular imaging is very bright. The possibility to look inside the body with eye spatial resolution and to look at the biochemical processes that are related to the onset of the diseases open a beautiful scenario in order to fit all the terrific achievements that have come from biology and from molecular medicine," Aime said. Barriers include the need for more sensitive probes and devices as scientists work to understand pathologies on the single-cell level. News-Medical.Net (5/12) LinkedInFacebookTwitterEmail this Story
  • A lower-dose approach to MPI
    Stress-first or stress-only myocardial perfusion imaging is gaining ground for assessment of possible or known coronary artery disease, but the approach has yet to see widespread use. The time-saving approach is considered suitable for patients whose images are expected to be normal. CardiovascularBusiness.com (4/25) LinkedInFacebookTwitterEmail this Story
  • Other News
  ADVERTISEMENT  
Technology and Exhibits 
  • PET/MR gains ground but likely won't eliminate PET/CT
    Clinical utility of PET/MR continues to expand, according to a growing body of research. However experts do not envision a total replacement of PET/CT. PET/MR is said to be a promising tool in imaging complex oncologic cases such as head and neck cancer and lung or liver lesions, and in pediatric cases for limiting radiation dose and need for sedation. PET/MR has shown an edge for imaging of the brain, spinal cord, testes and prostate and is being touted for its potential in cardiology and other applications. However, cost, lack of reimbursement and lack of trained technologists may hinder widespread adoption of the technology. Health Imaging magazine (5/1) LinkedInFacebookTwitterEmail this Story
  • Growth in neurology, cardiology fuel PET boom
    Neurology and cardiology are fueling a boom in PET service volume and equipment sales, according to a report from Bio-Tech Systems. PET procedure volume could reach 11 million annually by 2021, which might propel the radiopharmaceutical market to $5 billion by the same year. Overall, U.S. and international markets are projected to grow at 8% to 10% annually, reaching worldwide PET scanner sales of $1.4 billion by 2021, and growth forecasts will remain positive as physicians develop more confidence in using PET and as PET/MR systems continue to gain ground. AuntMinnie.com (free registration) (4/24) LinkedInFacebookTwitterEmail this Story
  

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual SNMMI endorsements. The news reported in SmartBrief does not necessarily reflect the official position of SNMMI.
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director: Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Editor: Melissa Turner

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2014 SmartBrief, Inc.® Legal Information